Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Live Nation Entertainment, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LYV | |
|---|---|---|
Market Cap | $29.60B | $42.71B |
Sector | Health | Industrials |
52-Week High | $491.22 | $186.59 |
52-Week Low | $205.48 | $125.61 |
Enterprise Value | $27.56B | $44.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Live Nation (LYV) trades at $185.71, up 0.58% with strong bullish technical signals from moving averages. The stock shows mixed fundamentals with a high P/E of 117.49 but beat Q2 2026 earnings expectations. Revenue growth remains robust at $25.2B in 2025, though net margins are thin at 0.51%. Recent insider sales and legal concerns create headwinds despite analyst optimism.
Outlook remains cautiously optimistic with 87% analyst buy ratings and a $209.54 price target suggesting 13% upside. Key risks include elevated valuation, debt levels, and regulatory scrutiny. The company's dominant live events position and strong demand provide growth catalysts, but execution on cost management will be critical for profitability improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
